Bank Julius Baer & Co
UBX

Bank Julius Baer & Co’s Unity Biotechnology UBX Stock Holding History

Bank Julius Baer & Co’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-821
Closed -$43K – 900
2020
Q4 		$43K Buy
+821
New +$39.6K ﹤0.01% 701

Other funds holding UBX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FFVM
Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return

Bank Julius Baer & Co's UBX Position: Q1 2021 in Review

Bank Julius Baer & Co sold out of Unity Biotechnology (UBX) in Q1 2021, closing a stake of 821 shares — an estimated $43K sold.

Bank Julius Baer & Co first reported a position in UBX in Q4 2020 and held it in 1 quarter. The position peaked at $43K in Q4 2020. 92 funds tracked by Wall St. Rank hold UBX as of Q1 2021.

  • Bank Julius Baer & Co reported no remaining Unity Biotechnology position as of Q1 2021 after selling out during the quarter.
  • Bank Julius Baer & Co sold 821 Unity Biotechnology shares in Q1 2021, an estimated $43K.
  • Bank Julius Baer & Co first reported a position in Unity Biotechnology in Q4 2020 and held it in 1 quarter.
  • Bank Julius Baer & Co's Unity Biotechnology position peaked at $43K in Q4 2020.
  • 92 funds tracked by Wall St. Rank held Unity Biotechnology as of Q1 2021.

Based on Bank Julius Baer & Co's 13F filing for Q1 2021, filed 10 May 2021.